Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Septerna, Inc. (SEPN : NSDQ)

• Company Description    Septerna Inc. is a clinical-stage biotechnology company pioneering a new era of GPCR oral small molecule drug discovery powered by its proprietary Native Complex Platform(TM). Septerna Inc. is based in SOUTH SAN FRANCISCO, Calif. Number of Employees: 130

• Price / Volume Information    Yesterday's Closing Price: $28.36 Daily Weekly Monthly 20 Day Moving Average: 329,525 shares Shares Outstanding: 45.08 (millions) Market Capitalization: $1,278.36 (millions) Beta: 2.21 52 Week High: $32.63 52 Week Low: $9.05 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.58% 8.03% 12 Week -6.34% -13.42% Year To Date 1.72% -7.93%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 250 EAST GRAND AVENUE - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-338-3533 fax: - investors@septerna.com https://septerna.com

• General Corporate Information    Officers Jeffrey Finer - Chief Executive Officer and Director Jeffrey Tong - Chairman and Director Gil M. Labrucherie - Chief Financial Officer Abraham Bassan - Director Bernard Coulie - Director Peer Information Septerna, Inc. (CORR.) Septerna, Inc. (RSPI) Septerna, Inc. (CGXP) Septerna, Inc. (BGEN) Septerna, Inc. (GTBP) Septerna, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 81734D104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/10/26 Share - Related Items Shares Outstanding: 45.08 Most Recent Split Date: (:1) Beta: 2.21 Market Capitalization: $1,278.36 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.61 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 3.38 Price/Cash Flow: - Price / Sales: 17.69 EPS Growth vs. Year Ago Period: 61.22% vs. Previous Quarter: 20.83% Sales Growth vs. Year Ago Period: 12,010.96% vs. Previous Quarter: 9.97% ROE 03/31/26 - -12.72 12/31/25 - -15.85 09/30/25 - -17.98 ROA 03/31/26 - -8.87 12/31/25 - -11.96 09/30/25 - -14.91 Current Ratio 03/31/26 - 4.71 12/31/25 - 4.73 09/30/25 - 6.53 Quick Ratio 03/31/26 - 4.71 12/31/25 - 4.73 09/30/25 - 6.53 Operating Margin 03/31/26 - -67.18 12/31/25 - -133.57 09/30/25 - -323.47 Net Margin 03/31/26 - -49.88 12/31/25 - -106.37 09/30/25 - -266.77 Pre-Tax Margin 03/31/26 - -49.40 12/31/25 - -106.35 09/30/25 - -267.49 Book Value 03/31/26 - 8.40 12/31/25 - 8.53 09/30/25 - 8.72 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00 Debt-to-Capital 03/31/26 - 0.00 12/31/25 - 0.00 09/30/25 - 0.00

Powered by Zacks Investment Research ©